Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
J Transl Med. 2023 Nov 27;21(1):858. doi: 10.1186/s12967-023-04739-7.
J Transl Med. 2023.
PMID: 38012658
Free PMC article.
Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.
Xie Y, Wang Y, Xu Z, Lu Y, Song D, Gao L, Yu D, Li B, Chen G, Zhang H, Feng Q, Zhang Y, Hu K, Huang C, Peng Y, Wu X, Mao Z, Shao J, Zhu W, Shi J.
Xie Y, et al.
J Biomed Sci. 2022 May 12;29(1):32. doi: 10.1186/s12929-022-00813-2.
J Biomed Sci. 2022.
PMID: 35546402
Free PMC article.
Clinical Trial.
Item in Clipboard
TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
Chang S, Xiao W, Xie Y, Xu Z, Li B, Wang G, Hu K, Zhang Y, Zhou J, Song D, Zhu H, Wu X, Lu Y, Shi J, Zhu W.
Chang S, et al.
Cancer Med. 2023 Dec;12(23):21321-21334. doi: 10.1002/cam4.6706. Epub 2023 Nov 9.
Cancer Med. 2023.
PMID: 37942576
Free PMC article.
Item in Clipboard
Cite
Cite